Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer (ARMANI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04678583
Recruitment Status : Recruiting
First Posted : December 22, 2020
Last Update Posted : February 5, 2021
Sponsor:
Collaborators:
KKS Dresden
German Cancer Research Center
Information provided by (Responsible Party):
Technische Universität Dresden

Brief Summary:
the ARMANI trial will test the hypothesis, if an anatomic resection (AR) improves long-term outcome vs. a non-anatomical resection (NAR) in patients undergoing surgery for RAS-mutated colorectal liver metastasis (CRLM).

Condition or disease Intervention/treatment Phase
Colorectal Liver Metastasis Procedure: Resection of colorectal liver metastases Not Applicable

Detailed Description:
Despite increasing application and success of personalized treatment in medical oncology, little progress has been made in personalized surgical cancer therapy. The ARMANI trial presents the first prospective, randomized trial to evaluate effectiveness and safety of molecular-guided resection in patients with colorectal liver metastasis (CRLM). While CRLM might be removed independently of the liver's segmental borders, retrospective data favor anatomic resections in the subgroup of patients with a mutation in the RAS oncogene. Therefore, the ARMANI trial will test the hypothesis, if an anatomic resection (AR) improves long-term outcome vs. a non-anatomical resection (NAR) in patients undergoing surgery for RAS-mutated CRLM. The trial will be carried out among 11 high-volume centers of hepato-biliary surgery in Germany. A total of 220 patients will be enrolled and randomized in a 1:1 ratio to undergo an AR vs. NAR. The primary endpoint is intrahepatic disease-free survival (iDFS). In addition, the study will provide important data on perioperative outcomes and quality of life for both surgical techniques. Given the trend among liver surgeons to aim for parenchymal-sparing operations to preserve liver parenchyma, a positive trial will be practice changing and present the first piece of high-level evidence on benefits of personalized surgical therapy guided by the tumor's mutational profile in patients with CRLM.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, controlled, patient and observer-blinded, confirmatory trial
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer
Actual Study Start Date : January 1, 2021
Estimated Primary Completion Date : December 31, 2024
Estimated Study Completion Date : December 31, 2024

Arm Intervention/treatment
Experimental: A - Anatomical resection
removal of the entire, tumor-bearing liver segment(s)
Procedure: Resection of colorectal liver metastases
Comparison of two liver surgery methods

Active Comparator: B - Non-anatomical resection
metastasectomy with a margin of healthy liver tissue irrespective of segmental borders
Procedure: Resection of colorectal liver metastases
Comparison of two liver surgery methods




Primary Outcome Measures :
  1. Intrahepatic disease-free survival (iDFS) [ Time Frame: 24 months ]
    Time from operation date to date of disease recurrence in the liver, followed up at intervals of three months for a maximum duration of 24 months or until death. Any new, solid lesion in the liver after resection of all CRLM that fulfils imaging criteria (CT, MRI) of a metastasis is counted as an iDFS event.


Secondary Outcome Measures :
  1. Assessment of additional oncological and perioperative outcomes: Intraoperative blood loss [mL] [ Time Frame: During surgery ]
    Intraoperative blood loss presents the amount of blood lost from skin incision until skin closure. Spilling water and ascites will be subtracted. Swabs will be squeezed and their content will also be sucked and added to the fluid collected in the suction containers.

  2. Assessment of additional oncological and perioperative outcomes: Operating time [min] [ Time Frame: During surgery ]
    Time from skin incision until placement of last skin staple/suture.

  3. Assessment of additional oncological and perioperative outcomes: Transfusion of blood, transfused packed red blood cells (PRBC), fresh frozen plasma (FFP) and / or platelet concentrate (PC) [units] [ Time Frame: 48 hours after surgery ]
    Administration of blood transfusions is documented for the intra- and postoperative period within 48 hours postoperatively.

  4. Assessment of additional oncological and perioperative outcomes: Duration of postoperative hospital stay [days] [ Time Frame: At day of discharge, assessed up to 90 days ]
    Postoperative day 1 until day of discharge

  5. Assessment of additional oncological and perioperative outcomes: Duration of postoperative intermediate/intensive care unit stay [days] [ Time Frame: At day of discharge, assessed up to 90 days ]
    Days on the intermediate care unit (IMC) or intensive care unit (ICU) after surgery. Patient's stay in the recovery room exceeding 24 hours is counted as ICU stay

  6. Assessment of additional oncological and perioperative outcomes: Frequency of peri-operative morbidity after resection [ Time Frame: 90 days after surgery ]
    Frequency of peri-operative complications after resection of the primary tumor

  7. Assessment of additional oncological and perioperative outcomes: Kind of peri-operative morbidity after resection [ Time Frame: 90 days after surgery ]
    Kind of peri-operative complications after resection of the primary tumor

  8. Assessment of additional oncological and perioperative outcomes: 90-day mortality [ Time Frame: 90 days after surgery ]
    Death due to any cause within 90 days after surgery

  9. Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: Platelet count [ Time Frame: pre-operativley, 5 days after surgery ]
    Platelet count will be measured preoperatively and on postoperative day 5

  10. Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: Alanine-aminotransferase [ Time Frame: pre-operatively, 5 days after surgery ]
    Levels of alanine-aminotransferase (ALT) will be measured preoperatively and on postoperative day 5

  11. Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: aspartate-aminotransferase [ Time Frame: pre-operatively, 5 days after surgery ]
    Levels of aspartate-aminotransferase (AST) will be measured preoperatively and on postoperative day 5

  12. Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: Gamma-glutamyl transferase [ Time Frame: pre-operatively, 5 days after surgery ]
    Levels of Gamma-glutamyl transferase (GGT) will be measured preoperatively and on postoperative day 5

  13. Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: International normalized ratio [ Time Frame: pre-operatively, 5 days after surgery ]
    Levels of international normalized ratio (INR) will be measured preoperatively and on postoperative day 5

  14. Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: Total bilirubin [ Time Frame: pre-operatively, 5 days after surgery ]
    Levels of total bilirubin will be measured preoperatively and on postoperative day 5

  15. Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: Albumin [ Time Frame: pre-operatively, 5 days after surgery ]
    Levels of albumin will be measured preoperatively and on postoperative day 5

  16. Assessment of additional oncological and perioperative outcomes: Frequency invasive re-interventions [ Time Frame: 30 days after surgery ]
    Invasive re-interventions such as placement of interventional drains, Endoscopic retrograde cholangiopancreatography (ERCP) with stent placement, chest tube placement, and re-laparotomy within 30 days after the index operation or during patients' initial hospital stay

  17. Assessment of additional oncological and perioperative outcomes: Kind of invasive re-interventions [ Time Frame: 30 days after surgery ]
    Invasive re-interventions such as placement of interventional drains, Endoscopic retrograde cholangiopancreatography (ERCP) with stent placement, chest tube placement, and re-laparotomy within 30 days after the index operation or during patients' initial hospital stay

  18. Assessment of additional oncological and perioperative outcomes: Number of patients with positive resection margins [ Time Frame: During surgery ]
    Detection of tumor at the resection margin will be counted as positive resection margin

  19. Assessment of additional oncological and perioperative outcomes: Frequency of Overall survival (OS) [ Time Frame: 24 month ]
    The overall survival of all patients is assessed between operation date to date of death of any cause

  20. Assessment of additional oncological and perioperative outcomes: Frequency of cancer-specific survival (CSS) [ Time Frame: 24 months ]
    The cancer-specific survival of all patients is assessed between operation date to date of death of colorectal cancer

  21. Assessment of additional oncological and perioperative outcomes: Frequency of disease-free survival (DFS) [ Time Frame: 24 month ]
    The disease-free survival of all patients is assessed from operation date to the date of either progressive or recurrent disease, or death of any cause

  22. Assessment of additional oncological and perioperative outcomes: Administration of adjuvant therapy [y/n] [ Time Frame: 24 month ]
    Adjuvant therapy is not recommended. However, the decision for adjuvant therapy is left at discretion of the local oncologist. The administration of adjuvant therapy and kind of chemotherapy protocols used will be documented for both groups.

  23. Assessment of additional oncological and perioperative outcomes: Frequency of oncological Re-interventions [y/n] [ Time Frame: 24 month ]
    Frequency of interventions for treatment of intra- and/or extrahepatic disease recurrence will be documented. These interventions include: Chemotherapy, Surgical resection, Local ablation (e.g. radiofrequency or microwave ablation, stereotactic irradiation), Selective internal radiotherapy (SIRT), other

  24. Assessment of additional oncological and perioperative outcomes: Kind of oncological Re-interventions [y/n] [ Time Frame: 24 month ]
    Kind of interventions for treatment of intra- and/or extrahepatic disease recurrence will be documented. These interventions include: Chemotherapy, Surgical resection, Local ablation (e.g. radiofrequency or microwave ablation, stereotactic irradiation), Selective internal radiotherapy (SIRT), other

  25. Assessment of additional oncological and perioperative outcomes: Assessment of "Quality of life" (QoL) [ Time Frame: 12 month ]
    Quality of life is measured preoperatively and at 90 days (± 7 days) and 12 months (± 7 days) postoperatively using the EORTC QLQ-C30 questionnaire (European Organisation for Research and Treatment of Cancer; Questionnaire for the assessment of Quality of Life of Cancer patients with the module dedicated to colorectal liver metastases (EORTC QLQ-LMC21); the questionnaire assesses multi-item scales, each item scoring from 1 to 4, a high score represents a high level of symptomatology or problems.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Colorectal cancer with RAS mutation (KRAS or NRAS)
  • Colorectal liver metastases (single or multiple)
  • Planned R0 resection of liver metastases (and primary tumor, if present)
  • Anatomical and non-anatomical liver resection technically feasible
  • Male and female patients, age ≥ 18 years
  • Written informed consent

Exclusion Criteria:

  • Extrahepatic metastases
  • Planned staged liver resection (e.g. two-stage hepatectomy)
  • Diagnosis of another cancer < 5 years prior to randomization Exceptions: curatively treated in situ cervical cancer, curatively resected non-melanoma skin cancer
  • Expected lack of compliance
  • Addiction or other illnesses which do not allow the person concerned to assess the nature and extent of the clinical trial and its possible consequences

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04678583


Contacts
Layout table for location contacts
Contact: Jürgen Weitz, Prof Dr med +49-(0)351 458 4850 juergen.weitz@ukdd.de

Locations
Layout table for location information
Germany
Department of Surgery at the University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University Not yet recruiting
Mannheim, Baden-Württemberg, Germany, 68167
Contact: Nuh Rahbari, PD Dr. med.    +49-(0)621 383 3591      
Department of Gastrointestinal-, Thoracic and Vascular Surgery University Hospital Carl Gustav Carus Technische Universität Dresden Recruiting
Dresden, Saxony, Germany, 01307
Contact: Jürgen Weitz, Prof Dr med         
Contact: Secretary    +49-(0)351 458 4850      
Sponsors and Collaborators
Technische Universität Dresden
KKS Dresden
German Cancer Research Center
Investigators
Layout table for investigator information
Principal Investigator: Jürgen Weitz, Prof Dr med Department of Gastrointestinal-, Thoracic and Vascular Surgery, University Hospital CGC
Principal Investigator: Nuh Rahbari, PD Dr med Department of Surgery at the University Medical Center Mannheim
Layout table for additonal information
Responsible Party: Technische Universität Dresden
ClinicalTrials.gov Identifier: NCT04678583    
Other Study ID Numbers: VTG-08
First Posted: December 22, 2020    Key Record Dates
Last Update Posted: February 5, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Neoplastic Processes
Pathologic Processes
Liver Diseases